Neurocrine Biosciences NBIX Insider Ownership

NASDAQ NBIX

$141.84 +3.49 (+2.52%)

At close: Sep 30, 2026 · 4:00 PM EDT

Insider Holdings by Owner

1.32Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

1.31%

▲+0.021% pp QoQ

Shares Held by Insiders

1.32Mn

filed for Sep 2026

▲+1.60% QoQ

Shares Outstanding

101.00Mn

101,000,000 shares

Direct Holdings

1.32Mn

Indirect: 0

Net Shares Traded (QoQ)

+20.86K

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Quarter ending 30 Sep, 2026

Neurocrine Biosciences's top three insider shareholders as of September 29, 2026 are Kevin Charles Gorman (Chief Executive Officer, 517.80K shares), Kyle Gano (Chief Executive Officer, 154.73K shares), Gary A Lyons (President And Ceo, 122.14K shares).

A detailed ownership breakdown for Neurocrine Biosciences is not available at this time.
Per Business Quant, insider holdings in NBIX make up 128.99% of the company, with 1.30Mn shares held against 101.00Mn outstanding.
Their holdings in Neurocrine Biosciences decreased 2.73%, from 1.34Mn shares to 1.30Mn shares over the prior quarter.
Among Neurocrine Biosciences's top brass, Ingrid Delaet (Chief Regulatory Officer) was the biggest buyer, purchasing 23.42K shares during the 90-day period from July 01, 2026 to September 29, 2026.
Meanwhile, Ingrid Delaet (Chief Regulatory Officer) topped selling at Neurocrine Biosciences, disposing of 40.30K shares over the same 90-day window.

Form 4 Holdings

Insiders Holding NBIX

Insiders 22

Shares held 1.32Mn

Of outstanding 1.31%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Kevin Charles Gorman	Chief Executive Officer	517,797	517,797	39.1%	15 Sep, 2026
2	Kyle Gano	Chief Executive Officer	154,728	154,728	11.7%	15 Sep, 2026
3	Gary A Lyons	President And Ceo	122,141	122,141	9.2%	21 May, 2026
4	Dimitri E. Grigoriadis	Chief Research Officer	82,273	82,273	6.2%	12 Oct, 2021
5	Eric Benevich	Chief Commercial Officer	67,297	67,297	5.1%	15 Sep, 2026
6	Darin Lippoldt	Chief Legal Officer	56,793	56,793	4.3%	15 Sep, 2026
7	William H Rastetter	Director	43,678	43,678	3.3%	21 May, 2026
8	Matt Abernethy	Chief Financial Officer	42,808	42,808	3.2%	15 Sep, 2026
9	Malcolm Lloyd-Smith	Chief Integration Officer	42,337	42,337	3.2%	08 Feb, 2023
10	Richard F Pops	Director	37,798	37,798	2.9%	21 May, 2026
11	Eiry Roberts	Chief Medical Officer	35,640	35,640	2.7%	14 Feb, 2025
12	Julie Cooke	Chief Human Resources Officer	24,025	24,025	1.8%	15 Sep, 2026
13	Jude Onyia	Chief Scientific Officer	22,647	22,647	1.7%	15 Sep, 2026
14	Ingrid Delaet	Chief Regulatory Officer	18,289	18,289	1.4%	15 Sep, 2026
15	Stephen A Sherwin	Director	14,860	14,860	1.1%	03 Sep, 2026
16	George J Morrow	Director	10,386	10,386	0.8%	21 May, 2026
17	David W. Boyer	Chief Corp. Affairs Officer	8,722	8,722	0.7%	15 Sep, 2026
18	Johanna Mercier	Director	6,853	6,853	0.5%	21 May, 2026
19	Christine A Poon	Director	4,753	4,753	0.4%	21 May, 2026
20	Shalini Sharp	Director	4,088	4,088	0.3%	21 May, 2026
21	Sanjay Chandru Keswani	Chief Medical Officer	3,281	3,281	0.2%	15 Sep, 2026
22	Leslie V Norwalk	Director	2,430	2,430	0.2%	30 Jul, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

2,770 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
09 Sep, 2026	Eric Benevich	Chief Commercial Officer	Acquired M	3,194	$43.24	$138.11K	66,562	Direct
09 Sep, 2026	Eric Benevich	Chief Commercial Officer	Disposed S	2,154	$154.61	$333.03K	64,408	Direct
09 Sep, 2026	Eric Benevich	Chief Commercial Officer	Disposed M	3,194	$0.00	$0	0	Direct
02 Sep, 2026	Stephen A Sherwin	Director	Disposed G	1,000	$0.00	$0	14,860	Direct
04 Aug, 2026	Jude Onyia	Chief Scientific Officer	Disposed G	2,409	$0.00	$0	20,996	Direct
28 Jul, 2026	Leslie V Norwalk	Director	Disposed S	1,250	$182.01	$227.51K	1,588	Direct
29 Jul, 2026	Leslie V Norwalk	Director	Acquired M	842	$139.43	$117.40K	2,430	Direct
29 Jul, 2026	Leslie V Norwalk	Director	Disposed M	842	$0.00	$0	2,140	Direct
10 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Acquired M	4,367	$106.02	$462.99K	20,592	Direct
09 Jul, 2026	Darin Lippoldt	Chief Legal Officer	Acquired M	10,000	$81.49	$814.90K	64,729	Direct
10 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Disposed S	4,367	$181.02	$790.51K	16,225	Direct
09 Jul, 2026	Darin Lippoldt	Chief Legal Officer	Disposed S	10,000	$179.60	$1.80Mn	54,729	Direct
10 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Disposed M	4,367	$0.00	$0	0	Direct
09 Jul, 2026	Darin Lippoldt	Chief Legal Officer	Disposed M	10,000	$0.00	$0	4,965	Direct
07 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Acquired M	3,401	$103.52	$352.07K	19,626	Direct
07 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Disposed S	3,401	$178.57	$607.31K	16,225	Direct
08 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Acquired M	2,737	$103.52	$283.33K	18,962	Direct
08 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Disposed S	2,737	$178.54	$488.67K	16,225	Direct
09 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Acquired M	8,433	$103.52	$872.98K	24,658	Direct
09 Jul, 2026	Ingrid Delaet	Chief Regulatory Officer	Disposed S	8,433	$178.72	$1.51Mn	16,225	Direct

Showing 1 to 20 of 2,770 transactions